Prestige Consumer Healthcare Inc (PBH) FinancialsPBHPrestige Consumer Healthcare Inc

Prestige Consumer Healthcare Inc. (PBH) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is International OTC Healthcare-Wellness, Sleep & Other, accounting for 100.7% of total sales, equivalent to $267.48M. Other significant revenue streams include North American OTC Healthcare-Women's Health and North American OTC Healthcare-Gastrointestinal. Understanding this composition is critical for investors evaluating how PBH navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Prestige Consumer Healthcare Inc. maintains a gross margin of 49.11%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 23.76%, while the net margin is 10.98%. These profitability ratios, combined with a Return on Equity (ROE) of 9.12%, provide a clear picture of how effectively PBH converts its operational activities into shareholder value.

In the context of the broader market, PBH competes directly with industry leaders such as NAMS and PRGO. With a market capitalization of $2.33B, it holds a significant position in the sector. When comparing efficiency, PBH's gross margin of 49.11% stands against NAMS's 100.00% and PRGO's 30.69%. Such benchmarking helps identify whether Prestige Consumer Healthcare Inc. is trading at a premium or discount relative to its financial performance.

Prestige Consumer Healthcare has shown fluctuating revenue with Q1 2027 sales of approximately $266 million, reflecting a 6.5% increase year-over-year. However, net income has also varied, with a reported net income of $29.2 million for Q1 2027, indicating some volatility in profitability. The gross margin has decreased to 50.02% in Q4 2026, down from 55.63% in Q4 2025, which raises concerns about cost management post-acquisition.